Management of patients with bleeding disorders
ISTH Academy, Robert Reid & Nigel Key, 201451
Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability
ISTH Academy, Jacqueline Halton, 203264
Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study
ISTH Academy, Charles Frost, 203265
A novel protein C–factor VII chimera provides new insights into the structural requirements for cytoprotective protease‐activated receptor 1 signaling
ISTH Academy, Roger Preston, 203266
Fibrinolysis: from blood to the brain
ISTH Academy, Robert Medcalf, 203267
Electronic alert system for improving appropriate thromboprophylaxis in hospitalized medical patients: a randomized controlled trial
ISTH Academy, Nils Kucher, 203268
Recommendations for standardized risk factor definitions in pediatric hospital‐acquired venous thromboembolism to inform future prevention trials: communication from the SSC of the ISTH
ISTH Academy, Brian R. Branchford, 203269
Autoimmune heparin‐induced thrombocytopenia
ISTH Academy, Andreas Greinacher, 203270
Thrombocytopenia and CD34 expression is decoupled from α‐granule deficiency with mutation of the first growth factor‐independent 1B zinc finger
ISTH Academy, William STEVENSON, 203271
Effect of late prophylaxis in hemophilia on joint status: a randomized trial
ISTH Academy, Marilyn Manco-Johnson, 203272
What the neighbors say
ISTH Academy, Session Speakers, 203273
Disease prevalence dependent failure rate in diagnostic management studies on suspected deep vein thrombosis: communication from the SSC of the ISTH
ISTH Academy, Frederikus Klok, 203274
Minimal factor XIII activity level to prevent major spontaneous bleeds: reply
ISTH Academy, Marzia Menegatti, 203275
Advanced cell‐based modeling of the royal disease: characterization of the mutated F9 mRNA
ISTH Academy, Jordi Barquinero, 203276
Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score
ISTH Academy, Laurent Bertoletti, 203277
Thrombin‐activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease
ISTH Academy, Robert Ariens, 203278
Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow‐up study
ISTH Academy, Francesco Dentali, 203279
ISTH Academy, Session Speakers, 203280
Stay Coagulated and Join the ISTH Today
ISTH Academy, Session Speakers, 203281
A gain‐of‐function mutation in TNFRSF13B is a candidate for predisposition to familial or sporadic immune thrombocytopenia
ISTH Academy, GuangSen Zhang, 203282
Long‐term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists
ISTH Academy, Michael Nagler, 203256
Issue Information
ISTH Academy, Session Speakers, 203257
Minimal factor XIII activity level to prevent major spontaneous bleeds: comment
ISTH Academy, Majid Naderi, 203258
Human pancreatic tumors grown in mice release tissue factor‐positive microvesicles that increase venous clot size
ISTH Academy, Nigel Mackman, 203259
Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective
ISTH Academy, Thomas A. Aloia, 203260
Emil Alfred Loeliger (Zürich 28 June 1924–Leiden 29 May 2017)
ISTH Academy, Session Speakers, 203261
An αβ antagonist prevents thrombosis without causing Fc receptor γ‐chain IIa‐mediated thrombocytopenia
ISTH Academy, Tur-Fu Huang, 203262
Extramedullary hematopoiesis: a new feature of inherited thrombocytopenias?
ISTH Academy, Carlo Zaninetti, 203263
Pre-analytical issues in the laboratory
ISTH Academy, Emmanuel Favaloro & Andrew Frelinger, 198093
World Thrombosis Day 2017 Webinar: Advances in Reducing the Disease Burden of Thrombosis
ISTH Academy, C. Michael Gibson, 202902
Galectin‐3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) Study
ISTH Academy, Aaron R. Folsom, 203327
Clot stability as a determinant of effective factor VIII replacement in hemophilia A
ISTH Academy, Lilley Leong, 203328
Near‐patient coagulation testing to predict bleeding after cardiac surgery: a cohort study
ISTH Academy, Andrew Mumford, 203329
Defects of splicing in antithrombin deficiency
ISTH Academy, María Eugenia De La Morena-Barrio, 203330
ISTH Academy, Session Speakers, 203331
Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review
ISTH Academy, Correspondence |Chi Braunreiter, 203332
Thromboelastography does not predict outcome in different etiologies of cirrhosis
ISTH Academy, Ton Lisman, 203333
Underestimation of N‐glycoPEGylated factor IX one‐stage clotting activity owing to contact activator‐impaired activation
ISTH Academy, Egon Persson, 203334
The impact of body weight on rivaroxaban pharmacokinetics
ISTH Academy, Jignesh Patel, 203335
Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases
ISTH Academy, Ton Lisman, 203336
Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
ISTH Academy, Ramin Artang, 203337
Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
ISTH Academy, Farès Moustafa, 203338
Structural origins of hemostasis and adaptive immunity
ISTH Academy, Jerry Ware, 203339
Neurosurgery in a patient at peak levels of rivaroxaban: taking into account all factors
ISTH Academy, Jan De Vlieger, 203340
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
ISTH Academy, Correspondence |Susumu Imazu, 203341
Preclinical evaluation of point‐of‐care prothrombin time as a biomarker test to guide prothrombin replacement therapy in coagulopathic bleeding
ISTH Academy, Correspondence|Clare A. Balendran, 203342
Indexing for a new journal: Research and Practice in Thrombosis and Haemostasis
ISTH Academy, Session Speakers, 203343
Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity?
ISTH Academy, Chris Ward, 203344
Identification of deep intronic individual variants in patients with hemophilia A by next‐generation sequencing of the whole factor VIII gene
ISTH Academy, Hiroshi Inaba, 203345
Principles and theory guiding development and delivery of patient education in disorders of thrombosis and hemostasis: Reviewing the current literature
ISTH Academy, Julia Hews-Girard, 203346
ARHGEF10 knockout inhibits platelet aggregation and protects mice from thrombus formation
ISTH Academy, Wen-Mei Fu, 203163
Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors
ISTH Academy, Connie Miller, 203164
Qualification of a select one‐stage activated partial thromboplastin time‐based clotting assay and two chromogenic assays for the post‐administration monitoring of nonacog beta pegol
ISTH Academy, Stefan Tiefenbacher, 203165
D‐dimer to guide the intensity of anticoagulation in Chinese patients after mechanical heart valve replacement: a randomized controlled trial
ISTH Academy, Zhenlu Zhang, 203166
The Michigan Risk Score to predict peripherally inserted central catheter‐associated thrombosis
ISTH Academy, Vineet Chopra, 203167
Effect of extended‐duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
ISTH Academy, C. Michael Gibson, 203168
Issue Information
ISTH Academy, Session Speakers, 203169
Bleeding‐related hospital admissions and 30‐day readmissions in patients with non‐valvular atrial fibrillation treated with dabigatran versus warfarin
ISTH Academy, Esther W. Chan, 203170
5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin‐induced thrombocytopenia antibodies
ISTH Academy, Yves Gruel, 203171
What the neighbors say
ISTH Academy, Session Speakers, 203172
Stay Coagulated and Join the ISTH Today
ISTH Academy, Session Speakers, 203173
A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor, in healthy subjects: comment
ISTH Academy, Victor Gurewich, 203174
Immune tolerance induced by platelet‐targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated
ISTH Academy, Qizhen Shi, 203175
Circulating tumor cell count and thrombosis in metastatic breast cancer
ISTH Academy, ATK Member, 203176
Comparison of multiple electrode aggregometry with lumi‐aggregometry for the diagnosis of patients with mild bleeding disorders
ISTH Academy, Paul Harrison, 203177
Vein wall remodeling in patients with acute deep vein thrombosis and chronic postthrombotic changes
ISTH Academy, Nicos Labropoulos, 203178
Treatment options for severe pulmonary embolism during pregnancy and the postpartum period: a systematic review
ISTH Academy, Marc Blondon, 203179
Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study
ISTH Academy, Reinhold Kreutz, 203180
Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics
ISTH Academy, X. Long Zheng, 203181
A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor, in healthy subjects: reply
ISTH Academy, Jin Zhou, 203182
Lipid specificity of the membrane binding domain of coagulation factor X
ISTH Academy, Emadeddin Tajkhorshid, 203183
Association between remote major venous thromboembolism risk factors and the risk of recurrence after a first unprovoked episode
ISTH Academy, Gregoire Le Gal, 203184
External validation of the DASH prediction rule: a retrospective cohort study
ISTH Academy, Alberto Tosetto, 203185
ISTH Academy, Session Speakers, 203186
Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH
ISTH Academy, Marc Carrier, 203187
Functional links between Disabled‐2 Ser723 phosphorylation and thrombin signaling in human platelets
ISTH Academy, Ching-Ping Tseng, 203188
Nurses Webinar: Nurse Led DOAC Clinics
ISTH Academy, Bunis Packham & Susan Jenkins, 198092
Considerations in the measurement of extended half-life factor products
ISTH Academy, Steve Kitchen & Stefan Tiefenbacher, 175151
Assessment of the protein interaction between coagulation factor XII and corn trypsin inhibitor by molecular docking and biochemical validation
ISTH Academy, Lodewijk V. Dekker, 203470
A kallikrein‐targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release
ISTH Academy, Bruce A. Sullenger, 203471
Altered β‐glycoprotein I expression on microparticles in the presence of antiphospholipid antibodies
ISTH Academy, Fariborz Mobarrez, 203472
Minimal factor XIII activity level to prevent major spontaneous bleeds
ISTH Academy, Flora Peyvandi, 203473
Stay Coagulated and Join the ISTH Today
ISTH Academy, Session Speakers, 203475
Will the real author please stand up?
ISTH Academy, Session Speakers, 203476
Preclinical safety and efficacy of andexanet alfa in animal models
ISTH Academy, Pamela B. Conley, 203477
In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients
ISTH Academy, Tim Preijers, 203478
Platelet production from induced pluripotent stem cells
ISTH Academy, Naoshi Sugimoto, 203479
Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a)
ISTH Academy, Michael B. Boffa, 203480
What the neighbors say
ISTH Academy, Session Speakers, 203481
Issue Information
ISTH Academy, Session Speakers, 203482
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment
ISTH Academy, Armando Tripodi, 203483
Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia
ISTH Academy, Jose Maria Bastida Bermejo, 203484
Assessing clinical probability of pulmonary embolism: prospective validation of the simplified Geneva score
ISTH Academy, Gregoire Le Gal, 203485
Factor XI‐deficient mice exhibit increased bleeding after injury to the saphenous vein
ISTH Academy, Nigel Mackman, 203486
A fusion protein of interleukin‐4 and interleukin‐10 protects against blood‐induced cartilage damage in vitro and in vivo
ISTH Academy, Lize Van Vulpen, 203487
Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH
ISTH Academy, Flora Peyvandi, 203488
Reproducibility of studies with genetically modified mice
ISTH Academy, Roger Lijnen, 203489
A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor
ISTH Academy, Renhao Li, 203491
Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study
ISTH Academy, Masaru Kato, 203492
Epidemiology of venous thromboembolism in Africa: a systematic review
ISTH Academy, Jean Jacques Noubiap, 203493